Literature DB >> 31639518

Does seronegative obstetric APS exist? "pro" and "cons".

Fabrizio Conti1, Laura Andreoli2, Francesca Crisafulli2, Silvia Mancuso1, Simona Truglia3, Maria G Tektonidou4.   

Abstract

Antiphospholipid Syndrome (APS) is the commonest treatable cause of recurrent miscarriage and pharmacological treatment of pregnant patients with antiphospholipid antibodies (aPL) should aim at preventing obstetric complications and maternal thrombotic events. Conventional treatment for patients with an established diagnosis of obstetric APS (OAPS), generally resulting in over 70-80% successful pregnancies. Since seropositive (SP)-APS and seronegative (SN)-APS patients had shown similar clinical profiles, patients with SN- OAPS, as well as SP-OAPS, should receive combined treatment in order to improve the pregnancy prognosis; indeed, current standard of care increased good pregnancy outcome in SN-APS, with similar effect to confirmed APS. The above data suggest that there are patients with the clinical manifestations of OAPS but persistently negative to conventional aPL that need to be identified to ensure adequate therapy and therefore a better prognosis. The clinical utility of non-criteria aPL in the diagnosis of SN-APS is still a matter of debate. In the last decade more and more studies have reported the presence of patients suffering from SN-APS in which non-conventional ("non-criteria") aPL might be present or antibodies may be detected using methodological approaches different from the traditional assays. To improve test standardization large prospective, multicenter, and multinational studies are needed. Therefore, when assessing a patient with clinical manifestations consistent with OAPS but aPL negative using the conventional available assays, the clinician should consider the possibility that the patient is affected with SN-APS.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Non-criteria antiphospholipid antibodies; Obstetric antiphospholipid syndrome; Seronegative obstetric antiphospholipid syndrome

Year:  2019        PMID: 31639518     DOI: 10.1016/j.autrev.2019.102407

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  8 in total

Review 1.  An Update on Antiphospholipid Syndrome.

Authors:  Eleni Xourgia; Maria G Tektonidou
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

Review 2.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

Review 3.  Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review.

Authors:  Pavla Bradacova; Ludek Slavik; Jana Ulehlova; Adela Skoumalova; Jana Ullrychova; Jana Prochazkova; Antonin Hlusi; Gayane Manukyan; Eva Kriegova
Journal:  Biomedicines       Date:  2021-02-08

4.  Longitudinal Analysis of Anti-cardiolipin and Anti-β2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients.

Authors:  Martina Frodlund; Tomas Walhelm; Charlotte Dahle; Christopher Sjöwall
Journal:  Front Med (Lausanne)       Date:  2021-02-24

5.  Antiphospholipid Antibodies From Women With Pregnancy Morbidity and Vascular Thrombosis Induce Endothelial Mitochondrial Dysfunction, mTOR Activation, and Autophagy.

Authors:  Carlos M Rodríguez; Manuela Velásquez-Berrío; Carolina Rúa; Marta Viana; Vikki M Abrahams; Angela P Cadavid; Angela M Alvarez
Journal:  Front Physiol       Date:  2021-11-29       Impact factor: 4.566

Review 6.  Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Ariadna Anunciación-Llunell; Joana Marques-Soares; Josep Pardos-Gea; Francesc Miró-Mur
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

7.  Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome.

Authors:  Jing Liu; Liting Zhang; Yijia Tian; Shuting Wan; Min Hu; Shasha Song; Meihua Zhang; Qian Zhou; Yu Xia; Xietong Wang
Journal:  J Cell Mol Med       Date:  2022-06-29       Impact factor: 5.295

8.  Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome.

Authors:  Pavla Bradáčová; Luděk Slavík; Adéla Skoumalová; Jana Úlehlová; Eva Kriegová; Gayane Manukyan; David Friedecký; Barbora Piskláková; Jana Ullrychová; Jana Procházková; Antonín Hluší
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.